J 2019

Colon Cancer and Perturbations of the Sphingolipid Metabolism

MACHALA, Miroslav, Jirina PROCHAZKOVA, Jirina HOFMANOVA, Lucie KRALIKOVA, Josef SLAVIK et. al.

Basic information

Original name

Colon Cancer and Perturbations of the Sphingolipid Metabolism

Authors

MACHALA, Miroslav (203 Czech Republic, guarantor), Jirina PROCHAZKOVA (203 Czech Republic), Jirina HOFMANOVA (203 Czech Republic), Lucie KRALIKOVA (203 Czech Republic), Josef SLAVIK (203 Czech Republic), Zuzana TYLICHOVA (203 Czech Republic), Petra OVESNÁ (203 Czech Republic, belonging to the institution), Alois KOZUBIK (203 Czech Republic) and Jan VONDRACEK (203 Czech Republic)

Edition

International Journal of Molecular Sciences, Basel, Multidisciplinary Digital Publishing Institute, 2019, 1422-0067

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10608 Biochemistry and molecular biology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 4.556

RIV identification code

RIV/00216224:14110/19:00112411

Organization unit

Faculty of Medicine

DOI

UT WoS

000504428300233

Keywords in English

colorectal cancer; colon cancer cells; sphingolipid; glycosphingolipid; colon cancer (CRC) sphingolipidomics; sphingosine-1-phosphate; lactosylceramide

Tags

Tags

International impact, Reviewed
Změněno: 21/7/2021 10:30, Mgr. Tereza Miškechová

Abstract

V originále

The development and progression of colorectal cancer (CRC), a major cause of cancer-related death in the western world, is accompanied with alterations of sphingolipid (SL) composition in colon tumors. A number of enzymes involved in the SL metabolism have been found to be deregulated in human colon tumors, in experimental rodent studies, and in human colon cancer cells in vitro. Therefore, the enzymatic pathways that modulate SL levels have received a significant attention, due to their possible contribution to CRC development, or as potential therapeutic targets. Many of these enzymes are associated with an increased sphingosine-1-phosphate/ceramide ratio, which is in turn linked with increased colon cancer cell survival, proliferation and cancer progression. Nevertheless, more attention should also be paid to the more complex SLs, including specific glycosphingolipids, such as lactosylceramides, which can be also deregulated during CRC development. In this review, we focus on the potential roles of individual SLs/SL metabolism enzymes in colon cancer, as well as on the pros and cons of employing the current in vitro models of colon cancer cells for lipidomic studies investigating the SL metabolism in CRC.